{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:40:50Z","timestamp":1789072850637,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13075-017-1488-5","type":"journal-article","created":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T20:30:20Z","timestamp":1514838620000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3395-4412","authenticated-orcid":false,"given":"Rieke","family":"Alten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Burkhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Feist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Rech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rubbert-Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard E.","family":"Voll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yedid","family":"Elbez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"key":"1488_CR1","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/annrheumdis-2016-210602","volume":"76","author":"B Combe","year":"2016","unstructured":"Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Varo-Gracia JM, et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis. 2016;76:948\u201359.","journal-title":"Ann Rheum Dis."},{"key":"1488_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges Jr SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68:1\u201325.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1488_CR3","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960\u201377.","journal-title":"Ann Rheum Dis."},{"key":"1488_CR4","doi-asserted-by":"crossref","unstructured":"Nam JL, Takase-Minegishi K, Ramiro S, Chatzidionysiou K, Smolen JS, van der Heijde D, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2017. \nhttps:\/\/doi.org\/10.1136\/annrheumdis-2016-210713\n\n.","DOI":"10.1136\/annrheumdis-2016-210713"},{"key":"1488_CR5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3\u201315.","journal-title":"Ann Rheum Dis."},{"key":"1488_CR6","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/ard.2006.066761","volume":"66","author":"GR Burmester","year":"2007","unstructured":"Burmester GR, Mariette X, Montecucco C, Monteagudo-Saez I, Malaise M, Tzioufas AG, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis. 2007;66:732\u20139.","journal-title":"Ann Rheum Dis."},{"key":"1488_CR7","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1136\/ard.2008.098467","volume":"68","author":"A Strangfeld","year":"2009","unstructured":"Strangfeld A, Hierse F, Kekow J, von Hinueber U, Tony HP, Dockhorn R, et al. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis. 2009;68:1856\u201362.","journal-title":"Ann Rheum Dis."},{"key":"1488_CR8","doi-asserted-by":"crossref","first-page":"e0123392","DOI":"10.1371\/journal.pone.0123392","volume":"10","author":"J Narvaez","year":"2015","unstructured":"Narvaez J, D\u00edaz-Torn\u00e9 C, Magallares B, Hernandez MV, Reina D, Corominas H, et al. Comparative effectiveness of tocilizumab with either methotrexate or leflunomide in the treatment of rheumatoid arthritis. PLoS One. 2015;10:e0123392.","journal-title":"PLoS One."},{"key":"1488_CR9","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/annrheumdis-2011-200003","volume":"71","author":"K Chatzidionysiou","year":"2012","unstructured":"Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, et al. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis. 2012;71:374\u20137.","journal-title":"Ann Rheum Dis."},{"key":"1488_CR10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.semarthrit.2011.06.005","volume":"41","author":"J Narvaez","year":"2011","unstructured":"Narvaez J, D\u00edaz-Torn\u00e9 C, Ruiz JM, Hernandez MV, Torrente-Segarra V, Ros S, et al. Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis. Semin Arthritis Rheum. 2011;41:401\u20135.","journal-title":"Semin Arthritis Rheum."},{"key":"1488_CR11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nrd1989","volume":"5","author":"L Moreland","year":"2006","unstructured":"Moreland L, Bate G, Kirkpatrick P. Abatacept. Nat Rev Drug Discov. 2006;5:185\u20136.","journal-title":"Nat Rev Drug Discov."},{"key":"1488_CR12","unstructured":"Orencia (125\u00a0mg solution for injection) Summary of Product Characteristics. \nhttp:\/\/www.medicines.org.uk\/emc\/medicine\/27216\/SPC\/\n\n. Accessed 19 Dec 2016."},{"key":"1488_CR13","first-page":"489","volume":"34","author":"HG N\u00fc\u00dflein","year":"2016","unstructured":"N\u00fc\u00dflein HG, Alten R, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, et al. Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study. Clin Exp Rheumatol. 2016;34:489\u201399.","journal-title":"Clin Exp Rheumatol."},{"key":"1488_CR14","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1136\/ard.2010.145268","volume":"70","author":"J Bathon","year":"2011","unstructured":"Bathon J, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, et al. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Ann Rheum Dis. 2011;70:1949\u201356.","journal-title":"Ann Rheum Dis."},{"key":"1488_CR15","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/ard.2009.119016","volume":"69","author":"P Emery","year":"2010","unstructured":"Emery P, Durez P, Dougados M, Legerton CW, Becker JC, Vratsanos G, et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis. 2010;69:510\u20136.","journal-title":"Ann Rheum Dis."},{"key":"1488_CR16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2014-206106","volume":"74","author":"P Emery","year":"2015","unstructured":"Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Barre E, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24\u00a0months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015;74:19\u201326.","journal-title":"Ann Rheum Dis."},{"key":"1488_CR17","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","volume":"353","author":"MC Genovese","year":"2005","unstructured":"Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353:1114\u201323.","journal-title":"N Engl J Med."},{"key":"1488_CR18","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMoa035075","volume":"349","author":"JM Kremer","year":"2003","unstructured":"Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003;349:1907\u201315.","journal-title":"N Engl J Med."},{"key":"1488_CR19","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1136\/ard.2010.139345","volume":"70","author":"JM Kremer","year":"2011","unstructured":"Kremer JM, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Westhovens R, et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis. 2011;70:1826\u201330.","journal-title":"Ann Rheum Dis."},{"key":"1488_CR20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2474-15-14","volume":"15","author":"H N\u00fc\u00dflein","year":"2014","unstructured":"N\u00fc\u00dflein H, Alten R, Galeazzi M, Lorenz HM, Boumpas D, Nurmohamed MT, et al. Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. BMC Musculoskelet Disord. 2014;15:14.","journal-title":"BMC Musculoskelet Disord."},{"key":"1488_CR21","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1136\/ard.2008.099218","volume":"68","author":"M Schiff","year":"2009","unstructured":"Schiff M, Pritchard C, Huffstutter JE, Rodriguez-Valverde V, Durez P, Zhou X, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis. 2009;68:1708\u201314.","journal-title":"Ann Rheum Dis."},{"key":"1488_CR22","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/art.22070","volume":"54","author":"M Weinblatt","year":"2006","unstructured":"Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum. 2006;54:2807\u201316.","journal-title":"Arthritis Rheum."},{"key":"1488_CR23","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1136\/annrheumdis-2015-208258","volume":"75","author":"C Peterfy","year":"2016","unstructured":"Peterfy C, Burmester GR, Bykerk VP, Combe BG, DiCarlo JC, Furst DE, et al. Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis. Ann Rheum Dis. 2016;75:1501\u20135.","journal-title":"Ann Rheum Dis."},{"key":"1488_CR24","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","volume":"144","author":"JM Kremer","year":"2006","unstructured":"Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144:865\u201376.","journal-title":"Ann Intern Med."},{"key":"1488_CR25","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/ard.2007.080002","volume":"67","author":"M Schiff","year":"2008","unstructured":"Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008;67:1096\u2013103.","journal-title":"Ann Rheum Dis."},{"key":"1488_CR26","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/annrheumdis-2013-203843","volume":"73","author":"M Schiff","year":"2014","unstructured":"Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73:86\u201394.","journal-title":"Ann Rheum Dis."},{"key":"1488_CR27","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/art.37711","volume":"65","author":"ME Weinblatt","year":"2013","unstructured":"Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013;65:28\u201338.","journal-title":"Arthritis Rheum."},{"key":"1488_CR28","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1136\/annrheumdis-2016-209124.121","volume":"75","author":"F Behrens","year":"2016","unstructured":"Behrens F, Rossmanith T, K\u00f6hm M, Alten R, Aringer M, Backhaus M, et al. FRI0199 Rituximab in Combination with Leflunomide: Results from A Multicenter Randomized Placebo Controlled Investigator Initiated Clinical Trial in Active Rheumatoid Arthritis (Amara-Study). Ann Rheum Dis. 2016;75:502.","journal-title":"Ann Rheum Dis."},{"key":"1488_CR29","unstructured":"Methotrexate 10\u00a0mg tablets Summary of Product Characteristics. \nhttps:\/\/www.medicines.org.uk\/emc\/medicine\/21378\n\n. Accessed 30 Mar 2017."},{"key":"1488_CR30","unstructured":"Methotrexate injection prescribing information. \nhttps:\/\/www.drugs.com\/pro\/methotrexate-injection.html\n\n. Accessed 30 Mar 2017."},{"key":"1488_CR31","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","volume":"75","author":"SC Gotestam","year":"2016","unstructured":"Gotestam SC, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795\u2013810.","journal-title":"Ann Rheum Dis."}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-017-1488-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,15]],"date-time":"2018-01-15T06:07:11Z","timestamp":1515996431000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-017-1488-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,2]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1488"],"URL":"https:\/\/doi.org\/10.1186\/s13075-017-1488-5","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,2]]},"article-number":"1"}}